Research Analysts Offer Predictions for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of Soleno Therapeutics in a report issued on Thursday, August 7th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($1.43) for the year, up from their previous forecast of ($2.10). The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Cantor Fitzgerald also issued estimates for Soleno Therapeutics’ FY2026 earnings at $1.95 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.44. The company had revenue of $32.66 million during the quarter, compared to the consensus estimate of $3.91 million.

A number of other research analysts have also recently commented on SLNO. Guggenheim raised their price target on Soleno Therapeutics from $97.00 to $106.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Piper Sandler raised their price target on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an “overweight” rating in a research report on Thursday, April 24th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. TD Cowen assumed coverage on Soleno Therapeutics in a research note on Monday, June 23rd. They issued a “buy” rating and a $110.00 price objective on the stock. Finally, Robert W. Baird set a $121.00 price objective on Soleno Therapeutics and gave the company an “outperform” rating in a research note on Friday, July 11th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $113.30.

Soleno Therapeutics Stock Up 4.1%

Shares of NASDAQ SLNO opened at $85.76 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.01 and a current ratio of 15.13. Soleno Therapeutics has a 52 week low of $41.50 and a 52 week high of $90.32. The stock has a market capitalization of $4.56 billion, a P/E ratio of -20.71 and a beta of -2.56. The stock’s fifty day moving average is $82.86 and its 200 day moving average is $68.62.

Institutional Trading of Soleno Therapeutics

A number of hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares in the last quarter. Moody Aldrich Partners LLC raised its position in shares of Soleno Therapeutics by 0.7% during the first quarter. Moody Aldrich Partners LLC now owns 29,810 shares of the company’s stock worth $2,130,000 after acquiring an additional 196 shares during the last quarter. Avanza Fonder AB raised its position in shares of Soleno Therapeutics by 14.8% during the first quarter. Avanza Fonder AB now owns 1,951 shares of the company’s stock worth $144,000 after acquiring an additional 251 shares during the last quarter. AlphaQuest LLC raised its position in shares of Soleno Therapeutics by 37.5% during the first quarter. AlphaQuest LLC now owns 983 shares of the company’s stock worth $70,000 after acquiring an additional 268 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Soleno Therapeutics by 8.6% during the first quarter. SG Americas Securities LLC now owns 4,397 shares of the company’s stock worth $314,000 after acquiring an additional 350 shares during the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,830 shares of Soleno Therapeutics stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total transaction of $316,970.80. Following the sale, the insider directly owned 13,206 shares of the company’s stock, valued at approximately $1,092,928.56. This trade represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 6.40% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.